For the expansion cohort, there were 10 patients with SCLC (25.0%), 9 with HER2-negative breast cancer (22.5%), 6 with mesothelioma (15.0%) and 15 with other cancer types (37.5%). This evidence concerns the gene ERBB2 and breast carcinoma.